Global Contact Us twitter LinkedIn gbt About Our Commitment Research Our MedicineInvestors & Media Careers ABOUT Our Company Leadership Board of Directors Contact Us OUR COMPANY GBT is working to discover, develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease Our goal is to transform the treatment of sickle cell disease (SCD), an overlooked rare condition, and help address the urgent needs of the community. Our mission is driven by the historical lack of understanding and attention given to SCD. Although the fundamental cause of SCD has been understood for decades, therapeutic innovation and access to care has significantly lagged. GBT’s medicine is the first treatment approved by the FDA to target an underlying cause of SCD. We are developing additional investigational treatments that have the potential to better the lives of patients. Our commitment to the SCD community We are driven by a deep and urgent desire to improve the care of SCD patients. Beyond developing medicines, we are working to shine a bright light on the disparities and inequalities faced by people living with SCD. To this end, in July 2019 we launched Sickle Cell Speaks, a national campaign focused on breaking down stigmas associated with SCD. Learn more Our history: we’re proud of all we have accomplished alongside the SCD community in our first 10 years and remain committed to our goal of changing the treatment paradigm in SCD. gbt Copyright 2021 Global Blood Therapeutics, Inc. Privacy Policy Online Tracking Opt-Out Guide Terms Of Use Community Guidelines P-VOX-US-00501 ABOUT Our Company Leadership Board of Directors Contact Us CAREERS OUR COMMITMENT Patients & Advocacy GBT’s Supported Conferences COVID-19 Information and Resources Corporate Giving The GBT Foundation Expanded Access RESEARCH Sickle Cell Disease Pipeline Externally Sponsored Research (ESR) Partnerships Publications OUR MEDICINE INVESTORS & MEDIA Company Summary Media Resources Press Releases Events & Presentations Quarterly Results Analyst Coverage Stock Information SEC Filings Governance Investor FAQs This site uses cookies to give you the best online experience. Learn more, including how to disable certain cookies on our Privacy Page. Accept × The health and safety of patients, healthcare professionals and our employees is our highest priority. Learn more about our response to the COVID-19 pandemic, including the direct support we are providing to the sickle cell disease community. COVID-19 Information and Resources Close